A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

NCT ID: NCT05279456

Last Updated: 2025-09-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-15
• Study Completion Date: 2023-12-31

Brief Summary

This study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose. This study will provide key data on SARS-CoV-2 antibody responses.

Detailed Description

The SARS-CoV-2 outbreak has caused millions of deaths globally. It has a particularly high mortality rate in elderly people and those with chronic disease where mortality rates can be as high as 20-30%. SARS-COV-2 vaccines remain a key priority to help fight the current pandemic. COVID-19 vaccines prevent symptomatic infection and may help reduce virus transmission. Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine has recently been approved by the Iranian FDA for emergency use in Iran in adults as a primary vaccine course and booster dose, after meeting its primary efficacy endpoint in a Phase 3 trial in 16,876 participants randomised 3:1 to receive Spikogen vaccine or saline placebo via two intramuscular doses 3 weeks apart where Spikogen vaccine demonstrated significant protection against serious infection with the delta variant. Approximately 5-10% of the broader Australian population and an even higher proportion of the indigenous populations remains unvaccinated despite current availability of these vaccines. One reason is that some people have medical contraindications to the current vaccines, such as serious allergies to the vaccine components such as polyethyleneglycol (PEG) in the mRNA vaccines.

Spikogen vaccine is made using a recombinant protein approach with the SARS-CoV-2 spike protein synthesized in an insect cell line grown in broth. Insect cell expression of recombinant protein is a well-established vaccine manufacturing approach. Spikogen vaccine also contains a unique Australian developed adjuvant called Advax-CpG55.2, which is added to the spike protein to make the vaccine more effective. AdvaxCpG55.2 has two components, one a natural plant sugar called inulin, and the second a short synthetic oligonucleotide polymer, known as CpG55.2 oligonucleotide.

Spikogen vaccine is designed to protect against SARS-CoV-2 infection. It has been shown to be effective against infection in hamster, ferret and monkey SARS-CoV-2 infection models.

This study will determine the immunogenicity of Spikogen in vaccine-naïve individuals. Spikogen will be administered as two doses 31 month apart with a third booster dose given either 1 or 3 months after the second dose.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Spikogen vaccine - accelerated arm

Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 2

Group Type: EXPERIMENTAL

Advax-CpG55.2 adjuvanted recombinant spike protein

Intervention Type: BIOLOGICAL

recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant

Spikogen vaccine - standard arm

Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 4

Group Type: EXPERIMENTAL

Advax-CpG55.2 adjuvanted recombinant spike protein

Intervention Type: BIOLOGICAL

recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant

Interventions

Advax-CpG55.2 adjuvanted recombinant spike protein

recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant

Intervention Type: BIOLOGICAL

Other Intervention Names

Spikogen vaccine

Eligibility Criteria

Inclusion Criteria

• Able to provide written informed consent
• Males or females* 18 years of age or older
• Understand and are likely to comply with planned study procedures and be available for all study visits.
• Have not previously had a Covid-19 vaccine and do not intend to have a non-study Covid-19 vaccine within the next 6 months

Exclusion Criteria

• History of Covid-19 vaccination.
• History of serious vaccine allergy.
• Pregnancy1
• Have received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial reporting period.
• Any medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Australian Respiratory and Sleep Medicine Institute

OTHER

Sponsor Role: collaborator

Vaxine Pty Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dimitar Sajkov, MBBS

Role: STUDY_DIRECTOR

ARASMI

Locations

ARASMI

Adelaide, South Australia, Australia

Countries

Australia

References

Li L, Honda-Okubo Y, Huang Y, Jang H, Carlock MA, Baldwin J, Piplani S, Bebin-Blackwell AG, Forgacs D, Sakamoto K, Stella A, Turville S, Chataway T, Colella A, Triccas J, Ross TM, Petrovsky N. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine. 2021 Sep 24;39(40):5940-5953. doi: 10.1016/j.vaccine.2021.07.087. Epub 2021 Aug 3.

Reference Type: BACKGROUND

PMID: 34420786 (View on PubMed)

Related Links

http://vaxine.net

Link to company website

Other Identifiers

AUST-C19-P3/4

Identifier Type: -

Identifier Source: org_study_id